Paper Details

  1. Home
  2. Paper Details

Antigen-specific active immunotherapy for ovarian cancer.

Author: BoezenH Marike, CohlenBen J, DaemenToos, HelfrichWijnand, LeffersNinke, MeliefCornelis Jm, NijmanHans W, PaijensSterre T, de BruynMarco

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

A Cochrane review of antigen-specific active immunotherapy for ovarian cancer found that despite advances in chemotherapy, the prognosis of ovarian cancer remains poor and antigen-specific active immunotherapy may be an alternative treatment.
Paper Details　
Original Abstract of the Article :
This is the second update of the review first published in the Cochrane Library (2010, Issue 2) and later updated (2014, Issue 9).Despite advances in chemotherapy, the prognosis of ovarian cancer remains poor. Antigen-specific active immunotherapy aims to induce tumour antigen-specific anti-tumour i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513204/

データ提供：米国国立医学図書館（NLM）

Fighting Ovarian Cancer: A New Frontier in Immunotherapy

Ovarian cancer is a serious disease with a poor prognosis. This study explores the potential of antigen-specific active immunotherapy as a new treatment for ovarian cancer. Imagine a desert oasis under attack by a relentless enemy; we need to find innovative ways to defend it. Antigen-specific active immunotherapy aims to stimulate the body's immune system to fight cancer cells. It's like training a camel caravan to protect the oasis from invaders. The researchers are hopeful that this approach could lead to more effective and durable treatments for ovarian cancer, offering a glimmer of hope for patients facing this challenging disease.

Antigen-Specific Active Immunotherapy: A Promising Weapon Against Ovarian Cancer

The study highlights the potential of antigen-specific active immunotherapy as a new weapon in the fight against ovarian cancer. By stimulating the body's immune system to target cancer cells, this approach offers a potentially more effective and long-lasting treatment compared to traditional therapies. It's like discovering a hidden spring of power within the desert, allowing us to fight back against a formidable enemy.

The Future of Cancer Treatment: A Journey of Hope and Innovation

This research underscores the importance of ongoing research and innovation in cancer treatment. As we continue to explore new approaches, such as immunotherapy, we are moving closer to a future where cancer is a manageable condition rather than a life-threatening disease. It's like exploring a vast desert, uncovering hidden pathways and resources that can lead to a brighter future.

Dr.Camel's Conclusion

This study provides a glimpse into the exciting future of cancer treatment. Antigen-specific active immunotherapy offers a promising new approach, holding the potential to revolutionize the fight against ovarian cancer. It's a reminder that even in the face of adversity, we can find hope and progress through continuous exploration and innovation.

Date :
  1. Date Completed 2018-10-05
  2. Date Revised 2022-08-30
Further Info :

Pubmed ID

30199097

DOI: Digital Object Identifier

PMC6513204

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.